



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

To,

Date: 20th May, 2023

BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai – 400001

Ref.: Company Code: 541096

Dear Sir / Madam,

Sub: Outcome of the Board Meeting and Submission of Audited Financial Results for the Quarter and Year ended on 31st March, 2023.

In compliance of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on 20th May, 2023, has considered and approved the Audited Financial Results for the Quarter and year ended 31st March, 2023 and taken on record Limited Review Report issued by the Statutory Auditors of the Company. The Board has also recommended payment of final dividend of Rs. 0.75 (Rupees Seventy-Five Paise Only) per Equity Share of Rs. 10/- each (fully paid-up) for the financial year ended March 31, 2023 and the same shall be payable subject to approval of the Shareholders at the ensuing Annual General Meeting ('AGM') of the Company.

In this respect, we hereby enclose following:

1. Audited Financial Results for the Quarter and Year ended 31st March, 2023.
2. Independent Auditor's Report on the said financial results (Standalone and Consolidated).
3. Declaration by the company as to the Unmodified Opinion expressed by the Statutory Auditors on Audited Financial Results (Standalone and Consolidated).

The meeting of Board of Directors commenced at 04.00 P.M. and concluded at 05:40 P.M.

Request you to please take the same on record.

Thanking You,

FOR BHARAT PARENTERALS LIMITED



Shyam Singh Rajpurohit
Company Secretary



Independent Auditor's Report on the consolidated financial results of Bharat Parenterals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.

TO THE BOARD OF DIRECTORS OF BHARAT PARENTERALS LIMITED

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying statement of consolidated financial results of Bharat Parenterals Limited (hereinafter referred to as the 'Holding Company') and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').


In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiary, the aforesaid consolidated financial results:

a. includes results of the following entity:

- 1) Innoxel Lifesciences Private Limited
- 2) Varenyam Biolifesciences Private Limited (Subsidiary w.e.f. 28th June, 2022)

b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard;

c. give a true and fair view in conformity with applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31st March, 2023.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These consolidated financial results have been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with applicable accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and



using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.


The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material



uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the Group to express an opinion on Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



The Consolidated Financial Results includes the results for the quarter ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah

Alok Shah


Partner

Membership No.042005

Place: Vadodara

Date: 20th May, 2023

UDIN: 23042005BGSQZY3084




STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2023

Sr. No.	Particular	Quarter Ended			Year Ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	A. Revenue from operations	5,097	5,902	5,231	21,798	21,201
	B. Other Income	31	348	219	1,174	778
	Total income	5,128	6,250	5,450	22,972	21,979
2	Expenses					
	A. Cost of materials consumed	3,771	3,187	3,268	14,607	13,272
	B. Purchase of Stock-in-Trade	2	5	33	116	166
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(791)	770	162	(975)	168
	D. Employee benefit expense	566	451	389	1,800	1,537
	E. Finance costs	80	79	31	219	97
	F. Depreciation, depletion and amortisation expense	144	144	156	588	666
	G. Other Expenses	927	1,225	940	4,263	3,285
	Total expenses	4,699	5,860	4,980	20,617	19,192
3	Total profit before tax	430	390	472	2,355	2,788
4	Tax expense					
	Current tax	276	135	180	840	830
	Deferred tax	(74)	7	(77)	(57)	(94)
	Short / (Excess) provision of tax in respect of earlier years	-	-	(29)	-	(29)
	Total tax expenses	202	143	75	783	706
5	Net Profit / (loss) for period	227	247	397	1,571	2,081
6	Other comprehensive Income					
	Items that will not be reclassified to profit or loss					
	Remeasurement of defined benefit obligation	29	(8)	(47)	6	(31)
	Income tax relating to Remeasurement of Defined benefit plans	(7)	2	12	(1)	8
	Other comprehensive Income for the year, net of taxes	22	(6)	(35)	4	(23)
7	Total Comprehensive Income for the period	249	242	362	1,576	2,058
	Net Profit attributable to:					
	Owners of the company	249	285	404	1,644	2,105
	Non Controlling Interest	(17)	(38)	(7)	(68)	(24)
	Other Comprehensive Income attributable to:					
	Owners of the company	22	(6)	(35)	4	(23)
	Non Controlling Interest	-	-	-	-	-
	Total Comprehensive Income for the period	271	280	369	1,648	2,082
	Owners of the company	271	280	369	1,648	2,082
	Non Controlling Interest	(17)	(38)	(7)	(68)	(24)
8	Paid up Equity Share Capital (Face Value of Rs 10/- per share)				577	577
9	Other Equity				17,702	16,005
10	Earnings per share					
	Basic (Rs.)	4.24	4.94	7.04	28.40	36.67
	Diluted (Rs.)	4.24	4.94	7.04	28.40	36.67

See accompanying notes to the Financial Results

- 1 The above results have been audited by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The Group has only one segment of activity, namely "Pharmaceuticals".
- 3 The Board has recommended Dividend of Equity shares at Rs 0.75 per share (face value Rs. 10/- each) i.e 7.50% for the year ended on 31st March, 2023 (Previous year Rs. Nil)
- 4 The figures for the quarter ended 31st March, 2023 and corresponding quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review.
- 5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
 For Bharat Parenterals Limited



Bharat R. Desai
 Managing Director
 Place : Vadodara
 Date : 20th May, 2023



BHARAT PARENTERALS LIMITED


Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF AUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT 31st MARCH, 2023


Sr. No.	Particulars	As at 31st March, 2023	As at 31st March, 2022
	ASSETS		
(1)	Non current Assets		
	(a) Property, Plant and Equipment	4,119	3,975
	(b) Capital work-in-progress	9,901	2,565
	(c) Investment Properties	99	108
	(d) <u>Financial Assets</u>		
	(i) Other Financial assets	321	301
	(e) Other Non Current Assets	2,166	1,282
(2)	Current assets		
	(a) Inventories	3,784	2,076
	(b) <u>Financial Assets</u>		
	(i) Investments	-	1,148
	(ii) Trade receivables	11,241	7,340
	(iii) Cash and cash equivalents	785	340
	(iv) Bank Balances other than Cash and cash equivalents	213	128
	(v) Loans	7	13
	(vi) Other financial assets	377	2,426
	(c) Other current assets	2,022	902
	Total Assets	35,034	22,606
	EQUITY AND LIABILITIES		
(1)	Equity		
	(a) Equity Share capital	577	577
	(b) Other Equity	17,702	16,005
	(c) Non-Controlling Interest	3,510	432
	Total equity attributable to equity holders of the Company	21,790	17,014
(2)	LIABILITIES		
	Non-Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	1,092	1,249
	(b) Provisions	133	94
	(c) Deferred tax liabilities (Net)	40	96
(3)	Current liabilities		
	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	3,882	526
	(ii) Trade payables		
	a) total outstanding dues of Micro Enterprises and Small Enterprises	402	365
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	5,435	2,011
	(iii) Other financial liabilities	1,009	620
	(b) Other current liabilities	1,091	433
	(c) Provisions	107	107
	(d) Current Tax Liability (Net)	53	92
	Total Liabilities	13,244	5,591
	Total Equity and Liabilities	35,034	22,606

By the order of Board of Director
For Bharat Parenterals LimitedBharat R. Desai
Managing Director
Place : Vadodara
Date : 20h May, 2023

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH, 2023

	Particulars	For the year ended 31st March, 2023	For the year ended 31st March, 2022
A	Cash flow from operating activities		
	Profit before income tax	2,355	2,788
	Adjustments for :		
	Share of (Profit)/Loss to minority	68	24
	Depreciation and amortisation expense	588	666
	(Gain)/ Loss on Sales of Property, Plant and Equipments (Net)	9	74
	Fair valuation of Investments through FVTPL	21	(113)
	(Gain)/ Loss on Sales of Investment (Net)	(55)	1
	Share Based Payment	53	(40)
	Finance Cost	219	97
	Unrealised Foreign exchange fluctuation	11	(48)
	Interest Income	(34)	(168)
	Operating profit before working capital changes	3,235	3,280
	Movements in working capital:		
	Current Assets		
	(Increase) / Decrease in trade receivables	(3,916)	(510)
	(Increase) / Decrease in inventories	(1,708)	167
	(Increase) / Decrease in other financial assets	1,932	(1,971)
	(Increase) / Decrease in Loans	7	(5)
	(Increase) / Decrease in other current assets	(1,120)	44
	(Increase) / Decrease in other non current assets	59	(75)
	Current Liabilities		
	Increase / (Decrease) in trade payables	3,464	(240)
	Increase / (Decrease) in provisions	45	21
	Increase / (Decrease) in other current liabilities	658	95
	Increase / (Decrease) in other financial liabilities	389	(339)
	Cash generated from operations :	3,045	468
	Direct taxes paid (net)	879	567
	Net cash from operating activities (A)	2,166	(99)
	Cash flows from investing activities		
B	Purchase of Property, plant and equipments (Including Capital work in progress including capital Advance)	(9,160)	(3,895)
	Proceeds of sale of Property, plant and equipments	151	8
	Purchase/(Sale) of investments	1,182	3,244
	(Increase) / Decrease Bank Balances other than Cash and cash interest Received	(85)	(53)
		130	33
	Net cash (used) in Investing activities (B)	(7,782)	(663)
	Cash flow from financing activities :		
C	Proceeds from issue of shares	-	45
	Proceeds from long term Borrowings	-	365
	Repayment of long term Borrowings	(124)	27
	Proceeds/(Repayment) of short term Borrowings	3,324	159
	Finance Cost	(219)	(97)
	Increase / (Decrease) in Non controlling Interest	3,079	437
	Net cash (used) in financing activities (C)	6,060	935
	NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]	444	172
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	340	168
	Balances with banks		
	(a) In current accounts	717	336
	(b) In Cash Credit Account	66	-
		783	336
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(1)	-
		782	336
	Cash on Hand	3	4
	CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	784	340

By the order of Board of Director
 For Bharat Parenterals Limited


 Bharat R. Desai
 Managing Director
 Place : Vadodara
 Date : 20th May, 2023



Independent Auditor's Report on Audited Standalone Quarterly Financial Results and Year to Date Results of the Bharat Parenterals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS OF BHARAT PARENTERALS LIMITED

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying statement of standalone financial results of Bharat Parenterals Limited (the company) for quarter and year ended 31st March, 2023 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended 31st March, 2023.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007

• Tel: +91 265 234 3483, +91 265 235 4359 • Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. • Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The statement has been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of



assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other matter

The Statement includes the results for the quarter ended 31st March, 2023 being the balancing figures between the audited figures in respect of full financial year ended 31st march, 2023 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For CNK & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036



Alok Shah
Partner
Membership No.042005
Place: Vadodara
Date: 20th May, 2023
UDIN: 23042005BGSQZX2016



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2023


Amount Rs. In Lakhs

Sr. No.	Particular	Quarter Ended			Year Ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	A. Revenue from operations	5,097	5,902	5,231	21,798	21,201
	B. Other Income	696	395	214	1,884	778
	Total income	5,793	6,297	5,445	23,682	21,979
2	Expenses					
	A. Cost of materials consumed	3,771	3,187	3,267	14,607	13,272
	B. Purchase of Stock-in-Trade	2	5	33	116	166
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(791)	770	162	(975)	168
	D. Employee benefit expense	490	429	383	1,693	1,526
	E. Finance costs	80	79	31	219	97
	F. Depreciation, depletion and amortisation expense	143	143	156	585	666
	G. Other Expenses	966	1,162	931	4,220	3,247
	Total expenses	4,661	5,774	4,964	20,465	19,142
3	Total profit before tax	1,132	524	481	3,217	2,837
4	Tax expense					
	Current tax	276	135	180	840	830
	Deferred tax	(74)	7	(77)	(57)	(94)
	Short / (Excess) provision of tax in respect of earlier years	-	-	(29)	-	(29)
	Total tax expenses	202	143	75	783	706
5	Net Profit / (loss) for period	929	381	406	2,434	2,130
6	Other comprehensive Income					
	Items that will not be reclassified to profit or loss					
	Remeasurement of defined benefit obligation	29	(8)	(47)	6	(31)
	Income tax relating to Remeasurement of Defined benefit plans	(7)	2	12	(1)	8
	Other comprehensive income for the year, net of taxes	22	(6)	(35)	4	(23)
7	Total Comprehensive Income for the period	951	375	371	2,438	2,107
8	Paid up Equity Share Capital (Face Value of Rs 10/- per share)				577	577
9	Other Equity				18,529	16,038
10	Earnings per share					
	Basic (Rs.)	16.19	6.60	7.08	42.40	37.11
	Diluted (Rs.)	16.19	6.60	7.08	42.40	37.11

See accompanying notes to the Financial Results

- The above results have been audited by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals."
- The Board has recommended Dividend of Equity shares at Rs 0.75 per share (face value Rs. 10/- each) i.e 7.50 % for the year ended on 31st March, 2023 (Previous year Rs. Nil)
- The figures for the quarter ended 31st March, 2023 and corresponding quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 20h May, 2023



BHARAT PARENTERALS LIMITED


Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT 31st MARCH, 2023

Sr. No.	Particulars	As at 31st March, 2023	As at 31st March, 2022
	ASSETS		
(1)	Non current Assets		
	(a) Property, Plant and Equipment	3,528	3,975
	(b) Capital work-in-progress	-	62
	(c) Investment Properties	99	108
	(d) <u>Financial Assets</u>		
	(i) Investments	3,840	482
	(ii) Other Financial assets	5,706	2,614
	(e) Other Non Current Assets	179	223
(2)	Current assets		
	(a) Inventories	3,784	2,076
	(b) <u>Financial Assets</u>		
	(i) Investments	-	1,148
	(ii) Trade receivables	11,240	7,340
	(iii) Cash and cash equivalents	635	333
	(iv) Bank Balances other than Cash and cash equivalents	107	128
	(v) Loans	7	13
	(vi) Other financial assets	377	2,426
	(c) Other current assets	1,301	872
	Total Assets	30,803	21,800
	EQUITY AND LIABILITIES		
(1)	Equity		
	(a) Equity Share capital	577	577
	(b) Other Equity	18,529	16,038
	Total equity attributable to equity holders of the Company	19,106	16,615
(2)	LIABILITIES		
	Non-Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	689	975
	(b) Provisions	133	94
	(c) Deferred tax liabilities (Net)	40	96
(3)	Current liabilities		
	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	3,882	526
	(ii) Trade payables		
	a) total outstanding dues of Micro Enterprises and Small Enterprises	402	339
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	4,391	1,915
	(iii) Other financial liabilities	1,001	620
	(b) Other current liabilities	998	424
	(c) Provisions	107	107
	(d) Current Tax Liability (Net)	54	92
	Total Liabilities	11,697	5,185
	Total Equity and Liabilities	30,803	21,800

By the order of Board of Director
For Bharat Parenterals Limited

Bharat R. Desai
Managing Director
Place : Vadodara
Date : 20h May, 2023

STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH, 2023

	Particulars	For the year ended 31st March, 2023 (Audited)	For the year ended 31st March, 2023 (Audited)
A	Cash flow from operating activities		
	Profit before income tax	3,217	2,837
	Adjustments for :		
	Depreciation and amortisation expense	585	666
	(Gain)/ Loss on Sales of Property, Plant and Equipments (Net)	(563)	74
	Fair valuation of Investments through FVTPL	21	(113)
	(Gain)/ Loss on Sales of Investment (Net)	(53)	1
	Share Based Payment	53	(40)
	Finance Cost	219	97
	Unrealised Foreign exchange fluctuation	11	(48)
	Interest Income	(183)	(168)
	Operating profit before working capital changes	3,306	3,305
	Movements in working capital:		
	Current Assets		
	(Increase) / Decrease in trade receivables	(3,915)	(510)
	(Increase) / Decrease in inventories	(1,708)	167
	(Increase) / Decrease in other financial assets	(1,140)	(4,284)
	(Increase) / Decrease in Loans	7	(5)
	(Increase) / Decrease in other current assets	(429)	102
	(Increase) / Decrease in other non current assets	59	(75)
	Current Liabilities		
	Increase / (Decrease) in trade payables	2,542	(362)
	Increase / (Decrease) in provisions	45	21
	Increase / (Decrease) in other current liabilities	575	90
	Increase / (Decrease) in other financial liabilities	381	(90)
	Cash generated from operations :	(278)	(1,641)
	Direct taxes paid (net)	878	567
	Net cash from operating activities (A)	(1,156)	(2,208)
	Cash flows from investing activities		
B	Purchase of Property, plant and equipments (Including Capital work in progress Including capital Advance)	(506)	(476)
	Proceeds of sale of Property, plant and equipments	990	8
	Purchase/(Sale) of investments	(2,177)	2,664
	(Increase) / Decrease Bank Balances other than Cash and cash	21	(53)
	Interest Received	279	33
	Net cash (used) in Investing activities (B)	(1,395)	2,176
	Cash flow from financing activities :		
C	Proceeds from issue of shares	-	45
	Proceeds from long term Borrowings	-	365
	Repayment of long term Borrowings	(253)	(247)
	Proceeds/ (Repayment) of short term Borrowings	3,324	159
	Finance Cost	(219)	(97)
	Net cash (used) in financing activities (C)	2,852	224
	NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]	301	193
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	333	140
	Balances with banks		
	(a) In current accounts	567	329
	(b) In Cash Credit Account	66	-
		633	329
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(1)	-
		632	329
	Cash on Hand	2	4
	CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	634	333

By the order of Board of Director
 For Bharat Parenterals Limited


 Bharat R. Desai
 Managing Director
 Place : Vadodara
 Date : 20h May, 2023





Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 20th May, 2023

To,
BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai – 400001

Ref.: Company Code: 541096

Dear Sir / Madam

Sub: Declaration with respect to Audit Report with Unmodified Opinion on Audited Financial Results (Standalone and Consolidated) of the Company for the year ended on 31st March, 2023.

In compliance of Regulation 33(3)(d) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended we hereby declare that the Auditors of the company has issued the Audit Report on Standalone and Consolidated Financial Result of the Company for the year ended on 31st March, 2023, with Unmodified Opinion.

Thanking You,

FOR BHARAT PARENTERALS LIMITED

Shyam Singh Rajpurohit
Company Secretary

